Table 4 Multivariate analysis on PLN and PALN metastasis in type I and type II ovarian cancer

Age(yr)

 ˂50

1

1

1

1

1

1

 ≥ 50

0.80(0.58–1.11)

0.85(0.72–1.01)

0.88(0.62–1.25)

0.90(0.75–1.06)

0.90 (0.45–1.76)

0.63(0.48–0.82)

Tumor Stage

 Stage T1

1

1

1

1

1

1

 Stage T2

4.40(2.59–7.47)

3.73(2.57–5.42)

5.26(3.18–9.05)

3.16(2.26–4.42)

3.79(1.07–13.51)

5.57(2.23–13.93)

 Stage T3

19.54(13.17–29.16)

15.70(11.37–21.67)

15.14(9.93–23.10)

9.76(7.33–12.98)

18.16(7.40–44.53)

26.44(11.72–59.63)

 Stage TxM1

33.04(14.96–72.93)

20.59(13.59–31.17)

23.92(10.34–55.37)

12.98(8.77–19.21)

21.11(4.09–108.88)

35.24(14.29–86.91)

Pathology Grade

 1

1

1

1

 2

0.84(0.50–1.38)

1

1.14(0.64–2.00)

1

0.77(0.25–2.37)

1

 3

1.12(0.79–1.58)

1.38(1.15–1.65)

2.28(1.57–3.33)

1.66(1.38–2.00)

1.24(0.61–2.51)

1.21(0.89–1.64)

Tumor size

 ≤ 5 cm

1

1

1

1

1

1

 > 5- ≤ 10 cm

0.96(0.59–1.55)

1.03(0.86–1.23)

1.19(0.68–2.08)

0.96(0.80–1.16)

1.26(0.46–3.45)

0.86(0.64–1.15)

 > 10- ≤ 15 cm

0.84(0.52–1.37)

0.85(0.70–1.04)

1.21(0.70–2.10)

1.14(0.94–1.40)

1.00(0.35–2.84)

0.85(0.61–1.17)

 > 15- ≤ 20 cm

1.03(0.60–1.76)

0.76(0.57–1.00)

1.31(0.71–2.40)

1.01(0.76–1.33)

1.03(0.32–3.31)

0.51(0.30–0.87)

 > 20 cm

0.74(0.40–1.39)

0.54(0.35–0.84)

1.80(0.97–3.37)

1.24(0.85–1.80)

0.69(0.17–2.86)

0.59(0.28–1.25)